Announcements Trials
Browse Landscape

Phase

Phase 2 68Phase 1 26Phase 3 21Phase 1/2 13Phase 2/3 5Phase EARLY_PHASE1 3Phase NA 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Urethral Neoplasms 1Ureteral Neoplasms 1Pancreatic Neoplasms 1Hydronephrosis 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Radiotherapy 17Specimen Handling 16Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11fludarabine 9Fluorodeoxyglucose F18 9X-Rays 8Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4Radiosurgery 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Disulfides × 1 year × Clear all
NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02812420 2026-03-05

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
54 enrolled

Hydronephrosis, Ureteral Neoplasms, Urethral Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Recruiting
90 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡